Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial

OBJECTIVE: To assess long‐term safety, tolerability, and efficacy of once‐daily oral atogepant 60 mg in adults with migraine. BACKGROUND: Atogepant is an oral, small‐molecule, calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of episodic migraine. METHODS: A 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Tepper, Stewart J., Reuter, Uwe, Blumenfeld, Andrew M., Hutchinson, Susan, Xia, Jing, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107835/
https://www.ncbi.nlm.nih.gov/pubmed/36651532
http://dx.doi.org/10.1111/head.14439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107835/
https://www.ncbi.nlm.nih.gov/pubmed/36651532
http://dx.doi.org/10.1111/head.14439

Ejemplares similares